Bokf Na Has $7.60 Million Position in Bristol-Myers Squibb (NYSE:BMY)

Bokf Na boosted its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 23.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 143,343 shares of the biopharmaceutical company’s stock after buying an additional 26,816 shares during the quarter. Bokf Na’s holdings in Bristol-Myers Squibb were worth $7,596,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BMY. McClarren Financial Advisors Inc. raised its position in shares of Bristol-Myers Squibb by 532.7% in the 4th quarter. McClarren Financial Advisors Inc. now owns 1,879 shares of the biopharmaceutical company’s stock worth $96,000 after acquiring an additional 1,582 shares in the last quarter. Institute for Wealth Management LLC. raised its position in shares of Bristol-Myers Squibb by 1.0% in the 4th quarter. Institute for Wealth Management LLC. now owns 30,056 shares of the biopharmaceutical company’s stock worth $1,542,000 after acquiring an additional 296 shares in the last quarter. Great Diamond Partners LLC raised its position in shares of Bristol-Myers Squibb by 9.2% in the 4th quarter. Great Diamond Partners LLC now owns 4,372 shares of the biopharmaceutical company’s stock worth $224,000 after acquiring an additional 367 shares in the last quarter. Global Assets Advisory LLC bought a new position in shares of Bristol-Myers Squibb in the 1st quarter worth about $5,161,000. Finally, Principal Securities Inc. bought a new position in shares of Bristol-Myers Squibb in the 4th quarter worth about $1,139,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Performance

NYSE BMY traded up $5.18 on Friday, hitting $50.45. 36,636,434 shares of the stock traded hands, compared to its average volume of 15,289,099. The business’s fifty day moving average is $41.76 and its two-hundred day moving average is $46.79. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.41. The firm has a market capitalization of $102.27 billion, a price-to-earnings ratio of -16.27, a PEG ratio of 19.02 and a beta of 0.44. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The business had revenue of $12.20 billion during the quarter, compared to analyst estimates of $11.54 billion. During the same period in the prior year, the company earned $1.75 earnings per share. Bristol-Myers Squibb’s revenue was up 8.7% compared to the same quarter last year. As a group, equities analysts anticipate that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.76%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s payout ratio is currently -77.42%.

Wall Street Analyst Weigh In

BMY has been the subject of several research analyst reports. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Barclays dropped their price target on Bristol-Myers Squibb from $43.00 to $41.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 10th. StockNews.com downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 27th. Wells Fargo & Company upped their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 18th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $45.00 price target on shares of Bristol-Myers Squibb in a research note on Monday, July 22nd. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $57.73.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.